Certified by Founder Lodge
Blue Owl Capital
United States - New York
INVESTOR
1 Disclosed Funding Rounds $200,000,000
10 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Blue Owl Capital (NYSE: OWL) is a global alternative asset manager with more than $138 billion in assets under management as of December 31, 2022. Anchored by a strong permanent capital base,
| Company | Date | Round | Raised |
|---|---|---|---|
 Mirador Therapeutics |
March, 26 ,2024 | Unknown | $400,000,000 |
 CloudPay |
August, 09 ,2024 | Unknown | $120,000,000 |
 Axonius |
March, 08 ,2022 | Series E | $200,000,000 |
 6sense |
January, 20 ,2022 | Series E | $200,000,000 |
 Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
 Vestwell |
December, 21 ,2023 | Unknown | $125,000,000 |
| CloudPay |
August, 09 ,2024 | Unknown | $120,000,000 |
| Mirador Therapeutics |
March, 26 ,2024 | Unknown | $400,000,000 |
| Alterome Therapeutics, Inc |
April, 09 ,2024 | Series B | $132,000,000 |
| CloudPay |
August, 09 ,2024 | Unknown | $120,000,000 |
Founderpath
Truework
Finix
Farther
TeamApt Inc.
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
